MacroGenics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“Like enoblituzumab, MGD009 is thought to possess anti-tumor activity across a wide range of cancer types, a claim derived from pre-clinical experiments in animal and test tube studies.” Read the following document
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It is focused on three therapeutic areas: Oncology, Autoimmune Disorders and Infectious Diseases. The company’s proprietary technology platforms include Dual-Affinity Re-Targeting (DART) Therapeutics, which allow to incorporate multiple specificities within a single molecule; FC Optimization, enhances antibody-dependent functions; and Cancer Stem Cell, which provides a unique discovery tool to identify cancer targets shared by both tumor-initiating cells and differentiated cancer cells. Its infectious disease portfolio includes antibody-based therapeutics for the treatment of infectious diseases from pathogens, such as dengue, smallpox and H5N1. The company’s autoimmune program, teplizumab, is an anti-CD3 antibody developed for the prevention and treatment of early onset diabetes. MacroGenics was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD. [Source: MarketWatch]
Company Website: https://www.macrogenics.com